The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Oral Hypoglycemic Drugs Market Research Report 2025
Synopsis
The global Oral Hypoglycemic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Oral Hypoglycemic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Hypoglycemic Drugs.
Report Scope
The Oral Hypoglycemic Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oral Hypoglycemic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oral Hypoglycemic Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
AstraZeneca
Johnson & Johnson
GlaxoSmithKline
Merck & Co
Eli Lilly
Sanofi
Takeda Pharmaceuticals
Novo Nordisk
Servier Laboratories
Boehringer Ingelheim
Bristol-Myers Squibb
Segment by Type
Sulfonylureas (SU)
Double Guanidine
Glucosidase Inhibitor
Insulin Synergist
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oral Hypoglycemic Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oral Hypoglycemic Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Oral Hypoglycemic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Oral Hypoglycemic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Hypoglycemic Drugs.
Report Scope
The Oral Hypoglycemic Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oral Hypoglycemic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oral Hypoglycemic Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
AstraZeneca
Johnson & Johnson
GlaxoSmithKline
Merck & Co
Eli Lilly
Sanofi
Takeda Pharmaceuticals
Novo Nordisk
Servier Laboratories
Boehringer Ingelheim
Bristol-Myers Squibb
Segment by Type
Sulfonylureas (SU)
Double Guanidine
Glucosidase Inhibitor
Insulin Synergist
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oral Hypoglycemic Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oral Hypoglycemic Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Oral Hypoglycemic Drugs Market Overview
1.1 Product Overview and Scope of Oral Hypoglycemic Drugs
1.2 Oral Hypoglycemic Drugs Segment by Type
1.2.1 Global Oral Hypoglycemic Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Sulfonylureas (SU)
1.2.3 Double Guanidine
1.2.4 Glucosidase Inhibitor
1.2.5 Insulin Synergist
1.3 Oral Hypoglycemic Drugs Segment by Application
1.3.1 Global Oral Hypoglycemic Drugs Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Oral Hypoglycemic Drugs Market Size Estimates and Forecasts
1.4.1 Global Oral Hypoglycemic Drugs Revenue 2019-2030
1.4.2 Global Oral Hypoglycemic Drugs Sales 2019-2030
1.4.3 Global Oral Hypoglycemic Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Oral Hypoglycemic Drugs Market Competition by Manufacturers
2.1 Global Oral Hypoglycemic Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Oral Hypoglycemic Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Oral Hypoglycemic Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Oral Hypoglycemic Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Oral Hypoglycemic Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oral Hypoglycemic Drugs, Product Type & Application
2.7 Oral Hypoglycemic Drugs Market Competitive Situation and Trends
2.7.1 Oral Hypoglycemic Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Oral Hypoglycemic Drugs Players Market Share by Revenue
2.7.3 Global Oral Hypoglycemic Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Oral Hypoglycemic Drugs Retrospective Market Scenario by Region
3.1 Global Oral Hypoglycemic Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Oral Hypoglycemic Drugs Global Oral Hypoglycemic Drugs Sales by Region: 2019-2030
3.2.1 Global Oral Hypoglycemic Drugs Sales by Region: 2019-2024
3.2.2 Global Oral Hypoglycemic Drugs Sales by Region: 2025-2030
3.3 Global Oral Hypoglycemic Drugs Global Oral Hypoglycemic Drugs Revenue by Region: 2019-2030
3.3.1 Global Oral Hypoglycemic Drugs Revenue by Region: 2019-2024
3.3.2 Global Oral Hypoglycemic Drugs Revenue by Region: 2025-2030
3.4 North America Oral Hypoglycemic Drugs Market Facts & Figures by Country
3.4.1 North America Oral Hypoglycemic Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Oral Hypoglycemic Drugs Sales by Country (2019-2030)
3.4.3 North America Oral Hypoglycemic Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Oral Hypoglycemic Drugs Market Facts & Figures by Country
3.5.1 Europe Oral Hypoglycemic Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Oral Hypoglycemic Drugs Sales by Country (2019-2030)
3.5.3 Europe Oral Hypoglycemic Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oral Hypoglycemic Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Oral Hypoglycemic Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Oral Hypoglycemic Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Oral Hypoglycemic Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Oral Hypoglycemic Drugs Market Facts & Figures by Country
3.7.1 Latin America Oral Hypoglycemic Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Oral Hypoglycemic Drugs Sales by Country (2019-2030)
3.7.3 Latin America Oral Hypoglycemic Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Oral Hypoglycemic Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Oral Hypoglycemic Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Oral Hypoglycemic Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Oral Hypoglycemic Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oral Hypoglycemic Drugs Sales by Type (2019-2030)
4.1.1 Global Oral Hypoglycemic Drugs Sales by Type (2019-2024)
4.1.2 Global Oral Hypoglycemic Drugs Sales by Type (2025-2030)
4.1.3 Global Oral Hypoglycemic Drugs Sales Market Share by Type (2019-2030)
4.2 Global Oral Hypoglycemic Drugs Revenue by Type (2019-2030)
4.2.1 Global Oral Hypoglycemic Drugs Revenue by Type (2019-2024)
4.2.2 Global Oral Hypoglycemic Drugs Revenue by Type (2025-2030)
4.2.3 Global Oral Hypoglycemic Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Oral Hypoglycemic Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Oral Hypoglycemic Drugs Sales by Application (2019-2030)
5.1.1 Global Oral Hypoglycemic Drugs Sales by Application (2019-2024)
5.1.2 Global Oral Hypoglycemic Drugs Sales by Application (2025-2030)
5.1.3 Global Oral Hypoglycemic Drugs Sales Market Share by Application (2019-2030)
5.2 Global Oral Hypoglycemic Drugs Revenue by Application (2019-2030)
5.2.1 Global Oral Hypoglycemic Drugs Revenue by Application (2019-2024)
5.2.2 Global Oral Hypoglycemic Drugs Revenue by Application (2025-2030)
5.2.3 Global Oral Hypoglycemic Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Oral Hypoglycemic Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Oral Hypoglycemic Drugs Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 AstraZeneca Oral Hypoglycemic Drugs Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Johnson & Johnson
6.3.1 Johnson & Johnson Corporation Information
6.3.2 Johnson & Johnson Description and Business Overview
6.3.3 Johnson & Johnson Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Johnson & Johnson Oral Hypoglycemic Drugs Product Portfolio
6.3.5 Johnson & Johnson Recent Developments/Updates
6.4 GlaxoSmithKline
6.4.1 GlaxoSmithKline Corporation Information
6.4.2 GlaxoSmithKline Description and Business Overview
6.4.3 GlaxoSmithKline Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GlaxoSmithKline Oral Hypoglycemic Drugs Product Portfolio
6.4.5 GlaxoSmithKline Recent Developments/Updates
6.5 Merck & Co
6.5.1 Merck & Co Corporation Information
6.5.2 Merck & Co Description and Business Overview
6.5.3 Merck & Co Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Merck & Co Oral Hypoglycemic Drugs Product Portfolio
6.5.5 Merck & Co Recent Developments/Updates
6.6 Eli Lilly
6.6.1 Eli Lilly Corporation Information
6.6.2 Eli Lilly Description and Business Overview
6.6.3 Eli Lilly Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Eli Lilly Oral Hypoglycemic Drugs Product Portfolio
6.6.5 Eli Lilly Recent Developments/Updates
6.7 Sanofi
6.6.1 Sanofi Corporation Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofi Oral Hypoglycemic Drugs Product Portfolio
6.7.5 Sanofi Recent Developments/Updates
6.8 Takeda Pharmaceuticals
6.8.1 Takeda Pharmaceuticals Corporation Information
6.8.2 Takeda Pharmaceuticals Description and Business Overview
6.8.3 Takeda Pharmaceuticals Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Takeda Pharmaceuticals Oral Hypoglycemic Drugs Product Portfolio
6.8.5 Takeda Pharmaceuticals Recent Developments/Updates
6.9 Novo Nordisk
6.9.1 Novo Nordisk Corporation Information
6.9.2 Novo Nordisk Description and Business Overview
6.9.3 Novo Nordisk Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Novo Nordisk Oral Hypoglycemic Drugs Product Portfolio
6.9.5 Novo Nordisk Recent Developments/Updates
6.10 Servier Laboratories
6.10.1 Servier Laboratories Corporation Information
6.10.2 Servier Laboratories Description and Business Overview
6.10.3 Servier Laboratories Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Servier Laboratories Oral Hypoglycemic Drugs Product Portfolio
6.10.5 Servier Laboratories Recent Developments/Updates
6.11 Boehringer Ingelheim
6.11.1 Boehringer Ingelheim Corporation Information
6.11.2 Boehringer Ingelheim Oral Hypoglycemic Drugs Description and Business Overview
6.11.3 Boehringer Ingelheim Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Boehringer Ingelheim Oral Hypoglycemic Drugs Product Portfolio
6.11.5 Boehringer Ingelheim Recent Developments/Updates
6.12 Bristol-Myers Squibb
6.12.1 Bristol-Myers Squibb Corporation Information
6.12.2 Bristol-Myers Squibb Oral Hypoglycemic Drugs Description and Business Overview
6.12.3 Bristol-Myers Squibb Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Bristol-Myers Squibb Oral Hypoglycemic Drugs Product Portfolio
6.12.5 Bristol-Myers Squibb Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oral Hypoglycemic Drugs Industry Chain Analysis
7.2 Oral Hypoglycemic Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oral Hypoglycemic Drugs Production Mode & Process
7.4 Oral Hypoglycemic Drugs Sales and Marketing
7.4.1 Oral Hypoglycemic Drugs Sales Channels
7.4.2 Oral Hypoglycemic Drugs Distributors
7.5 Oral Hypoglycemic Drugs Customers
8 Oral Hypoglycemic Drugs Market Dynamics
8.1 Oral Hypoglycemic Drugs Industry Trends
8.2 Oral Hypoglycemic Drugs Market Drivers
8.3 Oral Hypoglycemic Drugs Market Challenges
8.4 Oral Hypoglycemic Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Oral Hypoglycemic Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Oral Hypoglycemic Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Oral Hypoglycemic Drugs Market Competitive Situation by Manufacturers in 2023
Table 4. Global Oral Hypoglycemic Drugs Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Oral Hypoglycemic Drugs Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Oral Hypoglycemic Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Oral Hypoglycemic Drugs Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Oral Hypoglycemic Drugs Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Oral Hypoglycemic Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Oral Hypoglycemic Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Oral Hypoglycemic Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Oral Hypoglycemic Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Oral Hypoglycemic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Hypoglycemic Drugs as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Oral Hypoglycemic Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Oral Hypoglycemic Drugs Sales by Region (2019-2024) & (K Units)
Table 18. Global Oral Hypoglycemic Drugs Sales Market Share by Region (2019-2024)
Table 19. Global Oral Hypoglycemic Drugs Sales by Region (2025-2030) & (K Units)
Table 20. Global Oral Hypoglycemic Drugs Sales Market Share by Region (2025-2030)
Table 21. Global Oral Hypoglycemic Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Oral Hypoglycemic Drugs Revenue Market Share by Region (2019-2024)
Table 23. Global Oral Hypoglycemic Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Oral Hypoglycemic Drugs Revenue Market Share by Region (2025-2030)
Table 25. North America Oral Hypoglycemic Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Oral Hypoglycemic Drugs Sales by Country (2019-2024) & (K Units)
Table 27. North America Oral Hypoglycemic Drugs Sales by Country (2025-2030) & (K Units)
Table 28. North America Oral Hypoglycemic Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Oral Hypoglycemic Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Oral Hypoglycemic Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Oral Hypoglycemic Drugs Sales by Country (2019-2024) & (K Units)
Table 32. Europe Oral Hypoglycemic Drugs Sales by Country (2025-2030) & (K Units)
Table 33. Europe Oral Hypoglycemic Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Oral Hypoglycemic Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Oral Hypoglycemic Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Oral Hypoglycemic Drugs Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Oral Hypoglycemic Drugs Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Oral Hypoglycemic Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Oral Hypoglycemic Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Oral Hypoglycemic Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Oral Hypoglycemic Drugs Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Oral Hypoglycemic Drugs Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Oral Hypoglycemic Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Oral Hypoglycemic Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Oral Hypoglycemic Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Oral Hypoglycemic Drugs Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Oral Hypoglycemic Drugs Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Oral Hypoglycemic Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Oral Hypoglycemic Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Oral Hypoglycemic Drugs Sales (K Units) by Type (2019-2024)
Table 51. Global Oral Hypoglycemic Drugs Sales (K Units) by Type (2025-2030)
Table 52. Global Oral Hypoglycemic Drugs Sales Market Share by Type (2019-2024)
Table 53. Global Oral Hypoglycemic Drugs Sales Market Share by Type (2025-2030)
Table 54. Global Oral Hypoglycemic Drugs Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Oral Hypoglycemic Drugs Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Oral Hypoglycemic Drugs Revenue Market Share by Type (2019-2024)
Table 57. Global Oral Hypoglycemic Drugs Revenue Market Share by Type (2025-2030)
Table 58. Global Oral Hypoglycemic Drugs Price (US$/Unit) by Type (2019-2024)
Table 59. Global Oral Hypoglycemic Drugs Price (US$/Unit) by Type (2025-2030)
Table 60. Global Oral Hypoglycemic Drugs Sales (K Units) by Application (2019-2024)
Table 61. Global Oral Hypoglycemic Drugs Sales (K Units) by Application (2025-2030)
Table 62. Global Oral Hypoglycemic Drugs Sales Market Share by Application (2019-2024)
Table 63. Global Oral Hypoglycemic Drugs Sales Market Share by Application (2025-2030)
Table 64. Global Oral Hypoglycemic Drugs Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Oral Hypoglycemic Drugs Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Oral Hypoglycemic Drugs Revenue Market Share by Application (2019-2024)
Table 67. Global Oral Hypoglycemic Drugs Revenue Market Share by Application (2025-2030)
Table 68. Global Oral Hypoglycemic Drugs Price (US$/Unit) by Application (2019-2024)
Table 69. Global Oral Hypoglycemic Drugs Price (US$/Unit) by Application (2025-2030)
Table 70. Pfizer Corporation Information
Table 71. Pfizer Description and Business Overview
Table 72. Pfizer Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Pfizer Oral Hypoglycemic Drugs Product
Table 74. Pfizer Recent Developments/Updates
Table 75. AstraZeneca Corporation Information
Table 76. AstraZeneca Description and Business Overview
Table 77. AstraZeneca Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. AstraZeneca Oral Hypoglycemic Drugs Product
Table 79. AstraZeneca Recent Developments/Updates
Table 80. Johnson & Johnson Corporation Information
Table 81. Johnson & Johnson Description and Business Overview
Table 82. Johnson & Johnson Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Johnson & Johnson Oral Hypoglycemic Drugs Product
Table 84. Johnson & Johnson Recent Developments/Updates
Table 85. GlaxoSmithKline Corporation Information
Table 86. GlaxoSmithKline Description and Business Overview
Table 87. GlaxoSmithKline Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. GlaxoSmithKline Oral Hypoglycemic Drugs Product
Table 89. GlaxoSmithKline Recent Developments/Updates
Table 90. Merck & Co Corporation Information
Table 91. Merck & Co Description and Business Overview
Table 92. Merck & Co Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Merck & Co Oral Hypoglycemic Drugs Product
Table 94. Merck & Co Recent Developments/Updates
Table 95. Eli Lilly Corporation Information
Table 96. Eli Lilly Description and Business Overview
Table 97. Eli Lilly Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Eli Lilly Oral Hypoglycemic Drugs Product
Table 99. Eli Lilly Recent Developments/Updates
Table 100. Sanofi Corporation Information
Table 101. Sanofi Description and Business Overview
Table 102. Sanofi Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Sanofi Oral Hypoglycemic Drugs Product
Table 104. Sanofi Recent Developments/Updates
Table 105. Takeda Pharmaceuticals Corporation Information
Table 106. Takeda Pharmaceuticals Description and Business Overview
Table 107. Takeda Pharmaceuticals Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Takeda Pharmaceuticals Oral Hypoglycemic Drugs Product
Table 109. Takeda Pharmaceuticals Recent Developments/Updates
Table 110. Novo Nordisk Corporation Information
Table 111. Novo Nordisk Description and Business Overview
Table 112. Novo Nordisk Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Novo Nordisk Oral Hypoglycemic Drugs Product
Table 114. Novo Nordisk Recent Developments/Updates
Table 115. Servier Laboratories Corporation Information
Table 116. Servier Laboratories Description and Business Overview
Table 117. Servier Laboratories Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Servier Laboratories Oral Hypoglycemic Drugs Product
Table 119. Servier Laboratories Recent Developments/Updates
Table 120. Boehringer Ingelheim Corporation Information
Table 121. Boehringer Ingelheim Description and Business Overview
Table 122. Boehringer Ingelheim Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Boehringer Ingelheim Oral Hypoglycemic Drugs Product
Table 124. Boehringer Ingelheim Recent Developments/Updates
Table 125. Bristol-Myers Squibb Corporation Information
Table 126. Bristol-Myers Squibb Description and Business Overview
Table 127. Bristol-Myers Squibb Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Bristol-Myers Squibb Oral Hypoglycemic Drugs Product
Table 129. Bristol-Myers Squibb Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Oral Hypoglycemic Drugs Distributors List
Table 133. Oral Hypoglycemic Drugs Customers List
Table 134. Oral Hypoglycemic Drugs Market Trends
Table 135. Oral Hypoglycemic Drugs Market Drivers
Table 136. Oral Hypoglycemic Drugs Market Challenges
Table 137. Oral Hypoglycemic Drugs Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Oral Hypoglycemic Drugs
Figure 2. Global Oral Hypoglycemic Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Oral Hypoglycemic Drugs Market Share by Type in 2023 & 2030
Figure 4. Sulfonylureas (SU) Product Picture
Figure 5. Double Guanidine Product Picture
Figure 6. Glucosidase Inhibitor Product Picture
Figure 7. Insulin Synergist Product Picture
Figure 8. Global Oral Hypoglycemic Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Oral Hypoglycemic Drugs Market Share by Application in 2023 & 2030
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Global Oral Hypoglycemic Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Oral Hypoglycemic Drugs Market Size (2019-2030) & (US$ Million)
Figure 15. Global Oral Hypoglycemic Drugs Sales (2019-2030) & (K Units)
Figure 16. Global Oral Hypoglycemic Drugs Average Price (US$/Unit) & (2019-2030)
Figure 17. Oral Hypoglycemic Drugs Report Years Considered
Figure 18. Oral Hypoglycemic Drugs Sales Share by Manufacturers in 2023
Figure 19. Global Oral Hypoglycemic Drugs Revenue Share by Manufacturers in 2023
Figure 20. The Global 5 and 10 Largest Oral Hypoglycemic Drugs Players: Market Share by Revenue in 2023
Figure 21. Oral Hypoglycemic Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 22. Global Oral Hypoglycemic Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 23. North America Oral Hypoglycemic Drugs Sales Market Share by Country (2019-2030)
Figure 24. North America Oral Hypoglycemic Drugs Revenue Market Share by Country (2019-2030)
Figure 25. U.S. Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Canada Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Europe Oral Hypoglycemic Drugs Sales Market Share by Country (2019-2030)
Figure 28. Europe Oral Hypoglycemic Drugs Revenue Market Share by Country (2019-2030)
Figure 29. Germany Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. France Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. U.K. Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Italy Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Russia Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Asia Pacific Oral Hypoglycemic Drugs Sales Market Share by Region (2019-2030)
Figure 35. Asia Pacific Oral Hypoglycemic Drugs Revenue Market Share by Region (2019-2030)
Figure 36. China Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Japan Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. South Korea Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. India Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Australia Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Taiwan Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Indonesia Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Thailand Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Malaysia Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Philippines Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Latin America Oral Hypoglycemic Drugs Sales Market Share by Country (2019-2030)
Figure 47. Latin America Oral Hypoglycemic Drugs Revenue Market Share by Country (2019-2030)
Figure 48. Mexico Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Brazil Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Argentina Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Middle East & Africa Oral Hypoglycemic Drugs Sales Market Share by Country (2019-2030)
Figure 52. Middle East & Africa Oral Hypoglycemic Drugs Revenue Market Share by Country (2019-2030)
Figure 53. Turkey Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Saudi Arabia Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. UAE Oral Hypoglycemic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. Global Sales Market Share of Oral Hypoglycemic Drugs by Type (2019-2030)
Figure 57. Global Revenue Market Share of Oral Hypoglycemic Drugs by Type (2019-2030)
Figure 58. Global Oral Hypoglycemic Drugs Price (US$/Unit) by Type (2019-2030)
Figure 59. Global Sales Market Share of Oral Hypoglycemic Drugs by Application (2019-2030)
Figure 60. Global Revenue Market Share of Oral Hypoglycemic Drugs by Application (2019-2030)
Figure 61. Global Oral Hypoglycemic Drugs Price (US$/Unit) by Application (2019-2030)
Figure 62. Oral Hypoglycemic Drugs Value Chain
Figure 63. Oral Hypoglycemic Drugs Production Process
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Distributors Profiles
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
